耐火性高胆固醇血症的新兴疗法:叙述性综述
Agnieszka Pawlos1, Etienne Khoury2, Daniel Gaudet2
1Department of Internal Diseases & Clinical Pharmacology, Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Kniaziewicza 1/5, 91-347, Lodz, Poland.
Future cardiology
|July 10, 2024
概括
耐药性高胆固醇血症 (RH) 是一种疾病,患者尽管接受治疗,但无法达到胆固醇的目标. 本综述探讨了RH疗法,强调低密度脂蛋白受体 (LDLR) 活性,以实现个性化治疗策略.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐药性高胆固醇血症 (RH) 影响了对标准降脂治疗有抗性的患者.
- 红血清显著增加心血管并发症的风险,特别是在家族性高胆固醇血症 (FH) 中.
- 红血病的患病率高于此前估计的.
研究的目的:
- 为RH提供了当前和新兴疗法的全面概述.
- 突出低密度脂蛋白受体 (LDLRs) 在RH治疗中的作用.
- 强调LDLR活性对个性化RH治疗的重要性.
主要方法:
- 关于RH疗法的文献综述.
- 基于基因的治疗方法的分析.
- 在治疗策略中对LDLR依赖性的评估.
主要成果:
- 目前对RH的治疗方法有限,需要新的方法.
- 新兴疗法,包括基于基因的选择,显示出希望.
- LDLR活性是RH治疗疗效的关键决定因素.
结论:
- 红需要比标准疗法之外的定制治疗策略.
- 了解和准LDLR对于有效的RH管理至关重要.
- 基于LDLR功能的个性化药物可以优化RH患者的结果.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
628
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
628
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
156
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
156
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430


